⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

July 31, 2025Global Cardiology

Self-administered intranasal etripamil: a breakthrough in PSVT first-line treatment

Mohmmad Khalid Awais Asif Sarah Rasheed

View at Publisher

Ask AI

Bookmark

Share

Key Points

The breakthrough treatment significantly alleviated symptoms associated with PSVT.
Clinical observations have shown notable improvements in patient symptoms, including palpitations.
Etripamil's effectiveness in treating arrhythmias was evaluated through an observational analysis.
These findings may enable better management strategies for patients with arrhythmias.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Self-administered etripamil improves PSVT treatment outcomes in patients, suggesting a new approach.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khalid et al. (2025) studied this question.

synapsesocial.com/papers/68c1a40954b1d3bfb60de7a2 https://doi.org/10.4081/cardio.2025.79

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia2024 · 5 citations
2Podcast on Self-administered Intranasal Etripamil for Symptomatic Paroxysmal Supraventricular Tachycardia: The RAPID Trialreview · 2023
3Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study2025 · 9 citations
4Paroxysmal Supraventricular Tachycardia Treatmentreview · 2026
5Etripamil: The First FDA-Approved Intranasal L-Type Calcium Channel Blocker for Acute Termination of Paroxysmal Supraventricular Tachycardiasystematic_review · 2026
6Intranasal ‘spray-in-the-pocket’ treatment for conversion of supraventricular tachycardia: safe, effective but not definiteeditorial · 2023
7Self‐Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE‐303 Studycohort · 2026 · 1 citations
8Etripamil: First Approval.review · 2026 · 1 citations
9Left atrial appendage occlusion in atrial fibrillation: contemporary techniques, clinical outcomes, and future directionsGlobal Cardiology · 2026
10GLP1 receptor agonists: the evolution of evidence for fracture risk, body composition, and clinical implicationsGlobal Cardiology · 2026

GMore from Global Cardiology